Dear shareholders and shareholder representatives:
As an independent director of Shandong Wohua Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company"), I have diligently fulfilled my responsibilities in accordance with the "Administrative Measures for Independent Directors of Listed Companies," "Corporate Governance Guidelines for Listed Companies," "Shenzhen Stock Exchange Listing Rules," and "Self-Regulatory Guidelines No. 1 for Main Board Listed Companies," as well as the Company's Articles of Association. I have effectively promoted the Company's standardized, stable, and healthy development while safeguarding the interests of the Company and the legitimate rights and interests of shareholders. I hereby report on my performance in 2025.
1. Independence
I possess the independence required by the "Administrative Measures for Independent Directors of Listed Companies" and "Corporate Governance Guidelines for Listed Companies," and I have conducted a self-assessment of my independence in accordance with regulatory rules, finding no circumstances that would affect my independence. As an independent director, I do not hold any position in the Company other than as a member of the Board's specialized committees, and I have no relationships with the Company or its controlling shareholders that could hinder my ability to make independent and objective judgments. I have submitted my self-assessment report to the Company's Board of Directors.
2. Performance Overview
In 2025, I was re-elected as an independent director of the Company. Adhering to the principles of responsibility to minority shareholders and fairness, I maintained a diligent and responsible attitude, actively communicated with the Company, and timely understood the Company's operational status. I attended meetings punctually and carefully reviewed the proposals presented at these meetings. Based on a thorough understanding of the actual situation and my professional capabilities and experience, I made independent judgments, provided independent opinions, and voted on all proposals submitted by the Company.
(1) Attendance at Board Meetings
During the reporting period, the Company held six board meetings, and I did not miss any. I reviewed all proposals at the attended board meetings and voted in favor of all proposals, with no opposing or abstaining votes.
(2) Attendance at Specialized Committee Meetings
- As the convener of the Compensation and Assessment Committee, I convened and chaired one meeting on April 11, 2025, to review the proposal regarding the total remuneration for senior management for 2024.
- As a member of the Audit Committee, I attended six meetings, with the topics discussed as follows: